The Edge, Genentech’s biannual newsletter, shines a light on those in the hemophilia community who refuse to let their bleeding disorder limit them. Each issue of The Edge offers a look into unique aspects of the community and individual stories from all walks of life.
Learn about Genentech's DE&I efforts when treating blood disorders.
See how the efforts of the World Federation of Hemophilia are paying off.
Hear a hemophilia patient reflect on what his condition has taught him.
Learn what gaming means to the community and how it's used to cope with hemophilia.
Read a letter from a person with hemophilia to his younger self.
Hear how our team of Hemophilia Community Clinical Education Managers provides support, in their own words.
Monitoring the safety of a drug during clinical trials AND after is called pharmacovigilance. “Pharma” comes from the Greek word “pharmakeia”—for drugs, medicines, or remedies. “Vigilance” is from the Latin “vigilantia,” meaning wakefulness, watchfulness, or attention.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.